Core Viewpoint - MiNK Therapeutics, Inc. has been selected for an oral presentation at the AACR IO Annual Meeting, showcasing interim data from its Phase 2 study of AgenT-797 in combination with botensilimab and balstilimab for treating refractory gastric cancer [1][2]. Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [1][2]. - The company is advancing a pipeline of both native and engineered iNKT programs, emphasizing scalable and reproducible manufacturing for off-the-shelf delivery [2]. Product Information - AgenT-797 is an allogeneic iNKT cell therapy that combines the cytotoxic capabilities of natural killer cells with the adaptive memory of T cells, allowing for a broad range of immune responses [3]. - The product is designed to be a scalable, "off-the-shelf" cell therapy, manufactured in Lexington, MA [4]. Presentation Details - The oral presentation will focus on biomarker analysis from the Phase 2 study of AgenT-797 in combination with botensilimab and balstilimab for PD-1 refractory gastroesophageal cancer [2]. - The presentation is scheduled for February 25, 2025, from 1:00 to 1:45 p.m. PST [2].

Core Insights - MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [1][6] - The company announced a presentation at the ASCO GI Symposium, highlighting the potential of its iNKT cell therapies in treating advanced cancers [1][5] Company Overview - MiNK Therapeutics is pioneering the discovery, development, and commercialization of iNKT cell therapies, with a focus on scalable and reproducible manufacturing for off-the-shelf delivery [6] - The company is headquartered in New York, NY, and actively engages with investors through its website and social media channels [6] Clinical Trials and Research - A Phase 2 trial is evaluating the combination of agenT-797 (iNKT cells), botensilimab, balstilimab, ramucirumab, and paclitaxel in patients with advanced gastroesophageal adenocarcinoma who have received prior therapy [8] - Previous Phase I trial data indicated long-term, durable responses and tolerability in patients with PD-1 refractory cancers, particularly in gastric cancer patients who showed significant clinical and immunologic responses [8] - MiNK plans to provide a clinical update from the ongoing Phase II study in the second half of 2025 [8] Presentation Details - The presentation at the ASCO GI Symposium will cover the Phase II study of agenT-797 in combination with other therapies for advanced gastroesophageal adenocarcinoma [5] - The session is scheduled for January 23, 2025, from 11:30 AM to 1:00 PM PST [5]

Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancerNEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the upcoming American Society of Clinical Oncology Gastrointestina ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------------|------------------------------------------------------------------|--------------------------------- ...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Paul Ibbett - Scientist Conference Call Participants Emily Bodnar - H.C. Wainwright Operator Thank you for standing by. I would like to welcome everyone to the MiNK Therapeutics Third Quarter 2024 Financial Results. I would now like t ...

EXHIBIT 99.1 MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immunemediated diseases, today announced results for the third quarter 2024. MiNK will host a conference call and webcast at 8:30 a.m ...

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its third quarter 2024 financial results before the market opens on November 14, 2024. MiNK executives will host a conference call and webcast at 8 ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, ...

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies and Autonomous Therapeutics, Inc. (Autonomous), a leader developing first-in-class, diseaseactivated RNA medicines, announced a research collaboration aimed at effectively targeting and treating metastatic tumors. This collaboration will leverage Autonomous' precision encrypted RNA™ (encRNA) techno ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------------------|------------------------------------------------------------------| | | | | For the transition period from | __ ...